| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13G · 1 security · passive | ||||||
|
Aclaris Therapeutics, Inc.
13G/A
ACRS · 00461U105
|
9.4% |
1/9/2026
Event 12/9/2025
|
||||
| Biosion, Inc. | 9.4% | |||||
| Bonita Biotech (HK) Ltd | 9.4% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.